Lisinopril - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for lisinopril and what is the scope of patent protection?
Lisinopril
is the generic ingredient in four branded drugs marketed by Azurity, Accord Hlthcare, Ascent Pharms Inc, Aurobindo, Chartwell Rx, Corepharma, Heritage Pharma, Hikma Intl Pharms, Invagen Pharms, Lupin, Prinston Inc, Rising, Sciegen Pharms Inc, Strides Pharma, Sun Pharm Inds Ltd, Teva, Watson Labs, Wockhardt Bio Ag, Merck, and Twi Pharms, and is included in twenty-two NDAs. There are nine patents protecting this compound. Additional information is available in the individual branded drug profile pages.Lisinopril has ten patent family members in eight countries.
There are twenty-one drug master file entries for lisinopril. Forty-five suppliers are listed for this compound.
Summary for lisinopril
International Patents: | 10 |
US Patents: | 9 |
Tradenames: | 4 |
Applicants: | 20 |
NDAs: | 22 |
Drug Master File Entries: | 21 |
Finished Product Suppliers / Packagers: | 45 |
Raw Ingredient (Bulk) Api Vendors: | 82 |
Clinical Trials: | 129 |
Patent Applications: | 7,495 |
Drug Prices: | Drug price trends for lisinopril |
Drug Sales Revenues: | Drug sales revenues for lisinopril |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for lisinopril |
What excipients (inactive ingredients) are in lisinopril? | lisinopril excipients list |
DailyMed Link: | lisinopril at DailyMed |
Recent Clinical Trials for lisinopril
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
University of Rochester | Early Phase 1 |
Medical College of Wisconsin | Early Phase 1 |
Trinity Hypertension & Metabolic Research Institute | Phase 4 |
Pharmacology for lisinopril
Drug Class | Angiotensin Converting Enzyme Inhibitor |
Mechanism of Action | Angiotensin-converting Enzyme Inhibitors |
Medical Subject Heading (MeSH) Categories for lisinopril
Anatomical Therapeutic Chemical (ATC) Classes for lisinopril
Paragraph IV (Patent) Challenges for LISINOPRIL
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
QBRELIS | Oral Solution | lisinopril | 1 mg/mL | 208401 | 1 | 2019-10-24 |
US Patents and Regulatory Information for lisinopril
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Watson Labs | LISINOPRIL | lisinopril | TABLET;ORAL | 076059-005 | Jul 1, 2002 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Lupin | LISINOPRIL | lisinopril | TABLET;ORAL | 077321-001 | Sep 9, 2005 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Wockhardt Bio Ag | LISINOPRIL | lisinopril | TABLET;ORAL | 078402-003 | Apr 19, 2007 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for lisinopril
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Merck | PRINIVIL | lisinopril | TABLET;ORAL | 019558-006 | Jan 28, 1994 | ⤷ Sign Up | ⤷ Sign Up |
Merck | PRINIVIL | lisinopril | TABLET;ORAL | 019558-003 | Dec 29, 1987 | ⤷ Sign Up | ⤷ Sign Up |
Merck | PRINIVIL | lisinopril | TABLET;ORAL | 019558-004 | Oct 25, 1988 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for lisinopril
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Hong Kong | 1258803 | 賴諾普利製劑 (LISINOPRIL FORMULATIONS) | ⤷ Sign Up |
Spain | 2886869 | ⤷ Sign Up | |
European Patent Office | 3960156 | FORMULATIONS DE LISINOPRIL (LISINOPRIL FORMULATIONS) | ⤷ Sign Up |
>Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.